Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits

Drug Metabolism and Disposition

Volumn 32, Issue 11, 2004, Pages 1293-1298

  Kunta, Jeevan R ^a,b   Lee, Sung Hack ^b   Perry, Barbara A ^c   Lee, Yong Hee ^d   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; FIRST PASS EFFECT; INTESTINE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; CATHETERS, INDWELLING; FEMALE; INTESTINES; LIVER; METABOLIC CLEARANCE RATE; RABBITS; VERAPAMIL;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 6944247631     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000752     Document Type: Article

References (40)

1. Amidon GL, Lennernas H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (NY) 12:413-420.
2. Bhatti MM and Foster RT (1997) Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. Biopharm Drug Dispos 18:387-396.
3. Boek-Dohalska L, Hodek P, Sulc M, and Stiborova M (2001) alpha-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem-Biol Interact 138:85-106.
4. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
5. Conrad S, Viertelhaus A, Orzechowski A, Hoogstraate J, Gjellan K, Schrenk D, and Kauffmann HM (2001) Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 156:81-91.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
7. Donato MT and Castell JV (2003) Strategies and molecular probes to investigate the role of cytochrome P450 in drag metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153-178.
8. Echizen H and Eichelbaum M (1986) Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 11:425-449.
9. Franklin MR (1995) Enhanced rates of cytochrome P450 metabolic- intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes. Drug Metab Dispos 23:1379-1382.
10. Fraser DJ, Feyereisen R, Harlow GR, and Halpert JR (1997) Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425-1432.
11. Freeman TC (1995) Parallel patterns of cell-specific gene expression during enterocyte differentiation and maturation in the small intestine of the rabbit. Differentiation 59:179-192.
12. Fromm MF, Busse D, Kroemer HK, and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
13. Gibaldi M and Ferner D (1982) Pharmacokinetics. Marcel Dekker, New York.
14. Grass GM and Sweetana SA (1989) A correlation of permeabilities for passively transported compounds in monkey and rabbit jejunum. Pharm Res (NY) 6:857-862.
15. Guo J, Ping Q, and Chen Y (2001) Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm 216:17-21.
16. Hoffman DJ, Seifert T, Borre A, and Nellans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res (NY) 12:889-894.
17. Itoh T, Ono K, Koido KI, Li YH, and Yamada H (2001) Stereoselectivity of the folate transporter in rabbit small intestine: studies with amethopterin enantiomers. Chirality 13:164-169.
18. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332-337.
19. Kunta JR, Perry BA, Sutyak JP, and Sinko PJ (2001) Development of a novel intestinal and vascular access port (IVAP) rabbit model to study regiospecific oral absorption pharmacokinetics. Comp Med 51:349-356.
20. Lankford SM, Bai SA, and Goldstein JA (2000) Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 28:981-986.
21. Lee YH, Perry BA, Lee HS, Kunta JR, Sutyak JP, and Sinko PJ (2001) Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharm Res (NY) 18:1721-1728.
22. McKinnon RA, Burgess WM, Gonzalez FJ, and McManus ME (1993) Metabolic differences in colon mucosal cells. Mutat Res 290:27-33.
23. Najjar TA and Saad SY (2001) Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits. Chemotherapy 47:128-135.
24. Nishibe Y, Wakabayashi M, Harauchi T, and Ohno K (1998) Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 28:549-557.
25. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
26. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, and Vyas KP (1996) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines and in Caco-2 cells. Drug Metab Dispos 24:634-642.
27. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, and Tweedie DJ (1998) Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357:27-36.
28. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res (NY) 12:1304-1310.
29. Sandstrom R, Karlsson A, Knutson L, and Lennernas H (1998) Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res (NY) 15:856-862.
30. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, and Schinkel AH (2000) Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdrI genes. Mol Pharmacol 57:188-197.
31. Sinko PJ, Kunta J, Usansky H, and Perry BA (2004) Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther 310:359-366.
32. Sugawara I, Akiyama S, Scheper RJ, and Itoyama S (1997) Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112:23-31.
33. Tam-Zaman N, Tarn YK, Tawfik S, and Wiltshire H (2004) Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res (NY) 21:436-442.
34. Tracy TS, Korzekwa KR, Gonzalez FJ, and Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545-552.
35. van Aubel RA, van Kuijck MA, Koenderink JB, Deen PM, van Os CH, and Russel FG (1998) Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells. Mol Pharmacol 53:1062-1067.
36. van Kuijck MA, Kool M, Merkx GF, Geurts vK, Bindels RJ, Deen PM, and van Os CH (1997) Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet 77:285-287.
37. von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, and Eichelbaum M (2001) Determination of in vivo absorption, metabolism and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 70:217-227.
38. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, and Smith BR (2004) Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172-177.
39. Weber A, Kaplan M, Chughtai SA, Cohn LA, Smith AL, and Unadkat JD (2001) CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. Biopharm Drug Dispos 22:157-168.
40. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.